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The immune response to a vascularized allograft involves a complex series of 
events, including T  cell activation.  A  critical marker of T  cell activation is the 
acquisition of stereospecific membrane receptors for the lymphokine, interleukin 
2  (IL-2) (1-4).  While resting T  cells lack  IL-2 receptors, in vitro studies (5,  6) 
indicate that essentially all lectin- or alloantigen-stimulated proliferating T  cells 
express  the  IL-2  receptor.  Moreover,  the  interaction  of  IL-2  with  receptor- 
bearing  cells  is  required  for the  clonal  expansion  of activated  T  cells  (1-13). 
Whereas engagement of the T  cell receptor for antigen is the first step in T  cell 
activation,  the interaction of IL-2 with  the newly expressed IL-2 receptor is a 
requisite step in the common pathway of activation of all T  cells. The extension 
of these in vitro findings to the process of allograft rejection in vivo has not been 
extensively studied. IL-2 is necessary to reconstitute the acute rejection response 
in  vivo in  T  cell-deprived rats (14).  However, direct evidence in  vivo that the 
IL-2 receptor is involved in allograft rejection has been lacking. 
The rat monoclonal antibody (mAb) M7/20 binds to the murine IL-2 receptor, 
as demonstrated by its capacity to bind activated but not resting T  cells in flow 
cytometry experiments,  to  prevent  IL-2-mediated  DNA  synthesis  in  an  IL-2- 
dependent cytotoxic T  lymphocyte cell line, to precipitate an N-glycosylated 58 
kilodalton glycoprotein, and to competitively inhibit binding of radiolabelled IL- 
2  (15).  As  such,  it offers an  opportunity to direct immunosuppressive  therapy 
selectively against  IL-2 receptor-bearing cells during allograft rejection. In this 
report, we examine the effect of administration of M7/20 on survival of cardiac 
allografts in mice. 
Materials and Methods 
Animals.  Inbred male mice, weighing 20-25 gm, of strains C57BL/10, B10.BR, and 
B10.AKM  (The Jackson  Laboratory, Bar  Harbor,  ME)  were  used  throughout.  These 
strains are completely mismatched for the H-2 locus,  but share the same genetic back- 
ground. 
Operative  Technique.  Vascularized,  heterotopic heart  allografts  were  performed as 
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FIGURE  1.  Survival  of C57BL/10  heart allografts in B10.AKM recipients. The survival of 
grafts  treated with M7/20  (open  circles) was significantly greater than  untreated  controls 
(closed circles) (p < 0.01) or grafts treated with RA3-2C2 (diamonds) (p < 0.05). 
originally described by Corry et al. (16).  The aorta was anastomosed to the abdominal 
aorta, and the pulmonary artery to the adjacent vena cava using standard microvascular 
techniques with  10-0 nylon suture (Ethicon,  Inc., Somerville, N  J) under 20× magnifica- 
tion. With completion of the anastomoses, and warming of the heart with Ringer's lactate 
at 37°C,  normal sinus rhythm was resumed.  Once proficiency with  this technique  was 
achieved, survival at 24 h routinely exceeded 90%. 
Function  of  the  transplanted  heart  was  assessed  by  daily  palpation  of ventricular 
contractions through  the abdominal wail.  Rejection  was defined as the cessation of all 
myocardial contractions,  which  was  confirmed  by laparotomy under  ether  anesthesia. 
Rejected hearts were removed, fixed in formalin, sectioned, and stained with hematoxylin 
and eosin. 
Preparation and Administration ofmAb.  The production and characterization of mAb 
M7/20 has been previously described (15).  M7/20,  a rat u, k, Ig was purified from the 
culture supernatants of cells grown in serum-free medium (Hanna Labs, Berkeley, CA). 
Supernatants  were  precipitated  with  40-50%  saturated  ammonium  sulfate,  dialyzed, 
passed over DEAE Affi-Gel Blue (Bio-Rad, Richmond, VA) in 20 mM Tris (pH 7.2) and 
100  mM  NaC1,  and  the eluate  was fractionated  on  Sepbadex  G-200  (Pbarmacia  Fine 
Chemicals, Piscataway, N  J), run  in  20  mM Tris (pH 7.2),  250  mM NaCI, and 0.5%  n- 
butanol.  Antibody  purity  was  assessed  by  sodium  dodecyl  sulfate-polyacrylamide gel 
electrophoresis. The hybridoma producing mAb RA3-2C2, which binds to pre-B cells and 
to  some  mature  B  cells,  was  obtained  from  the  American  Type  Culture  Collection 
(Rockville, MD), and the mAb was purified by the same procedure (17). 
Both  mAb were diluted  to a  final concentration  of 25 #g/ml in phosphate-buffered 
saline. Treated allograft recipients received 0.2  ml (5  #g) by intraperitoneal  injection, 
beginning on the day of transplant and continuing for a total of 10 daily doses. 
Statistical Analysis.  Survival  times  were  compared  using  Mann-Whitney  rank-sum 
analysis. 
Results 
Untreated  B 10.AKM  recipients  of C57BL/10  heart  allografts rejected  their 
grafts on days 8  (four subjects),  16, and 29 (Fig.  1).  In contrast,  treatment with 
M7/20  at a  dose  of 5  #g/mouse/d  for  10  d  in  this  strain  combination  caused 
indefinite survival (>90 d) of four of six grafts, with two rejecting at 20 and  31 
d  (Fig.  1), a  highly significant prolongation (p <  0.01). 
To confirm that these results were related to the specificity of M7/20  for the 
IL-2 receptor,  an additional  control  group of recipients was treated  with  RA3- 360  KIRKMAN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE  2.  Survival of B10.BR  heart  allografts  in  C57BL/I0  recipients.  The  survival of 
grafts  treated  with  M7/20  (open  circles) was  significantly greater  than  untreated  controls 
(closed circles) (p <  0.01). 
2C2, a  rat mAb of the same class as M7/20, which binds pre-B cells, but not T 
cells. Four B10.AKM recipients of C57BL/10 grafts rejected their grafts on days 
6,  9  (two mice), and  10, with a  fifth graft surviving for >90 d  (Fig.  1). These 
survival times were not different from the untreated controls, but were signifi- 
cantly shorter than those in animals treated with M7/20 (p <  0.05). 
To demonstrate that the results were not unique to one strain combination, a 
second set of experiments was performed using C57BL/10 recipients of B 10.BR 
grafts. Untreated control recipients rejected their grafts at 10 (two animals),  14, 
and  20 d  (two animals).  Treatment  with  M7/20  prolonged survival to  20,  27, 
34, and 38 d, with two grafts still  functioning at >60 d (p <  0.01) (Fig. 2). 
Discussion 
The precise mechanism by which a vascularized allograft is rejected remains a 
subject of intense investigation, but the participation  of T  cells in the process is 
unquestioned.  Moreover, the process of T  cell activation has been well studied 
in vitro (1-13). Alloantigenic activation of T  cells in vitro leads to the induction 
of IL-2 receptors on T  cell surface membranes, and the interaction of IL-2 with 
these receptors  is required  for T  cell  proliferation.  Whereas  the  receptor  for 
antigen  is  required  for  the  first  stage  of T  cell  activation,  in  which  prepro- 
grammed, antigen-specific cells are stimulated, induction of the IL-2 receptor is 
part of a common pathway that all T  cells must follow to produce immunity. 
The results presented  in  this report provide important  new in vivo evidence 
that IL-2 receptor-bearing cells are required for allograft rejection. Administra- 
tion of M7/20, an mAb known to bind to the mouse IL-2 receptor, significantly 
prolonged vascularized heart allograft survival in two separate H-2-incompatible 
strain combinations in mice. Indeed, several grafts survived indefinitely, although 
the antibody was administered only for the first 10 d posttransplant.  Such long- 
term engraftment  following cessation of therapy makes it unlikely that  M7/20 
prolongs graft survival by pharmacologic blockade of the I L-2 receptor. Whether 
or not such prolonged graft survival represents deletion of the responding T  cell 
clones is a subject of current investigation. 
In addition to supporting the role of IL-2 receptor-dependent mechanisms in K1RKMAN ET AL.  BRIEF  DEFINITIVE  REPORT  361 
graft rejection, these experiments suggest that the IL-2 receptor is an important 
new target for immunosuppression in clinical transplantation.  Since all recently 
activated  T  cells  express  IL-2  receptor,  all  relevant  clones  can  be  targeted, 
regardless of their antigen specificity. Moreover, as resting and memory T  cells 
do not express significant quantities of the receptor (18), specific immunosuppres- 
sion may be possible. 
Summary 
Administration of the monoclonal antibody M7/20, which binds to the murine 
interleukin-2 (IL-2) receptor, significantly prolongs cardiac allograft survival in 
two H-2-incompatible strain combinations of inbred mice. The results support 
the important role of the IL-2 receptor in the mechanism of graft rejection, and 
suggest its suitability as a target for immunosuppressive therapy. 
Received  for publication I April 1985. 
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